15:06 , Jul 15, 2019 |  BC Extra  |  Company News

Galapagos maintains independence, adds R&D firepower with $5.1 billion megadeal with Gilead

A partnership with Gilead allows Galapagos to nearly double the size of its clinical pipeline, with the potential to add new technology platforms via BD and ensures its independence into the next decade. Under the...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
10:57 , May 7, 2019 |  BioCentury  |  Finance

Confo’s €30M growth plan

Two pharma deals and early preclinical data from Confo’s GPCR-modulating compounds persuaded BioGeneration and Wellington to make their first investments in a company targeting G protein-coupled receptors. A €30 million ($33.6 million) series A round,...
23:55 , Mar 28, 2019 |  BC Extra  |  Clinical News

Filgotinib hits more RA endpoints

Gilead and Galapagos took a step closer to submitting regulatory applications for filgotinib to treat rheumatoid arthritis after the partners reported positive data from the two remaining Phase III trials of the oral Janus kinase-1...
03:03 , Jan 26, 2019 |  BioCentury  |  Product Development

Target wide, test narrow in lupus

While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
18:08 , Dec 7, 2018 |  BC Week In Review  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
00:27 , Dec 4, 2018 |  BC Extra  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
18:00 , Nov 9, 2018 |  BC Week In Review  |  Company News

MorphoSys shares jump amid Tremfya guidance, MOR208 data

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) shares rose Nov. 6 after the company said in its 3Q18 earnings that plaque psoriasis drug Tremfya guselkumab could generate 2018 royalties at the upper end of the biotech's previous guidance....